Sign in
4

Changes in Ownership

Lexeo Therapeutics, Inc. Filed Acc 0001415889-25-001859

Chief Financial Officer acquired 40,875 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Rasbach Kyle Chief Financial Officer 2025-01-17 Grant or award +40,875 40,875 D
Derivatives
Rasbach Kyle Chief Financial Officer 2025-01-17 Grant or award · Stock Option (right to buy) +245,250 245,250 D
Loading xslF345X05/form4-01222025_040101.xml…